(ALSMA) SMAIO - Ratings and Ratios
Exchange: PA •
Country: France •
Currency: EUR •
Type: Common Stock •
ISIN: FR0014005I80
Implantable Devices, Surgical Software, Medical Services
Description: ALSMA SMAIO
S.M.A.I.O S.A. provides software, implantable devices, and associated services to treat spinal pathologies requiring surgery. The company was incorporated in 2009 and is based in Saint-Priest, France., Web URL: https://smaio.com
Additional Sources for ALSMA Stock
ALSMA Stock Overview
| Market Cap in USD | 38m |
| Sector | Healthcare |
| Industry | Health Information Services |
| GiC Sub-Industry | Health Care Technology |
| IPO / Inception |
ALSMA Stock Ratings
| Growth Rating | -0.18 |
| Fundamental | -5.96 |
| Dividend Rating | 0.0 |
| Rel. Strength | 63.6 |
| Analysts | - |
| Fair Price Momentum | 5.31 EUR |
| Fair Price DCF | - |
ALSMA Dividends
Currently no dividends paidALSMA Growth Ratios
| Growth Correlation 3m | 58.4% |
| Growth Correlation 12m | 6.8% |
| Growth Correlation 5y | -14.2% |
| CAGR 5y | 1.22% |
| CAGR/Max DD 5y | 0.02 |
| Sharpe Ratio 12m | -0.08 |
| Alpha | 41.58 |
| Beta | -0.006 |
| Volatility | 55.36% |
| Current Volume | 3.5k |
| Average Volume 20d | 1.7k |
| Stop Loss | 5.5 (-5.2%) |
What is the price of ALSMA shares?
As of July 15, 2025, the stock is trading at EUR 5.80 with a total of 3,452 shares traded.
Over the past week, the price has changed by +0.87%, over one month by +53.44%, over three months by +62.01% and over the past year by +52.23%.
As of July 15, 2025, the stock is trading at EUR 5.80 with a total of 3,452 shares traded.
Over the past week, the price has changed by +0.87%, over one month by +53.44%, over three months by +62.01% and over the past year by +52.23%.
Is SMAIO a good stock to buy?
Neither. Based on ValueRay´s Fundamental Analyses, SMAIO is currently (July 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -5.96 and therefor a neutral outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ALSMA is around 5.31 EUR . This means that ALSMA is currently overvalued and has a potential downside of -8.45%.
Neither. Based on ValueRay´s Fundamental Analyses, SMAIO is currently (July 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -5.96 and therefor a neutral outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ALSMA is around 5.31 EUR . This means that ALSMA is currently overvalued and has a potential downside of -8.45%.
Is ALSMA a buy, sell or hold?
SMAIO has no consensus analysts rating.
SMAIO has no consensus analysts rating.
What are the forecasts for ALSMA share price target?
According to our own proprietary Forecast Model, ALSMA SMAIO will be worth about 5.7 in July 2026. The stock is currently trading at 5.80. This means that the stock has a potential downside of -1.03%.
According to our own proprietary Forecast Model, ALSMA SMAIO will be worth about 5.7 in July 2026. The stock is currently trading at 5.80. This means that the stock has a potential downside of -1.03%.
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 7 | 20.7% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 5.7 | -1% |